All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Resistance Mutations Present an Ongoing Challenge in Aggressive Hematologic Malignancies

February 28th 2023

With acquired resistance patterns emerging for nearly every agent, hematologic experts are looking closely at sequencing patterns, but more work needs to be done in aggressive malignancies in which mutations associated with resistance may be present before therapy even begins.

Novel Therapeutics Clinic Offers Access to Early-Phase Trials for Solid Tumors

February 28th 2023

To increase access to emerging cancer therapeutics and improve convenience for patients and researchers, Taussig Cancer Institute opened a dedicated Novel Therapeutics Clinic.

Enrollment Begins for Phase 2 Trial of IMNN-001 Plus Bevacizumab/Chemo in Advanced Ovarian Cancer

February 28th 2023

Enrollment has commenced for a phase 2 trial investigating the DNA-based interleukin-12 immunotherapy IMNN-001 in combination with bevacizumab and chemotherapy in patients with advanced ovarian cancer.

Wang Details Caveats to Standards of Care for Treating Patients With MCL

February 28th 2023

When treating patients with mantle cell lymphoma, early identification and appropriate frontline therapy remains critical, and therapies may vary for those 65 years and older compared with patients under the age of 65, with several additional factors also having a role in approaching treatment options for a new patient in the clinic.

Pembrolizumab Plus Standard Therapy Falls Short in mCRPC, EGFR-Mutant NSCLC Trials

February 28th 2023

The addition of pembrolizumab to standard therapies failed to improve survival outcomes in patients with metastatic castration-resistant prostate cancer in the KEYNOTE-641 trial and patients with EGFR-mutated non–small cell lung cancer in the KEYNOTE-789 trial.

FDA Approval Sought for Adjuvant Nivolumab for Completely Resected Stage IIB/C Melanoma

February 28th 2023

The FDA has accepted the supplemental biologics license application for nivolumab as an adjuvant treatment for patients with completely resected stage IIB or IIC melanoma.

Survivin-Targeted Anticancer Vaccine Undergoes Investigation in Metastatic Neuroendocrine Neoplasms

February 28th 2023

Novel treatment options are needed in neuroendocrine tumors, and advances in immunotherapy have not been optimized in this population.

Teclistamab Approval Adds to Bucket of Relapsed/Refractory Multiple Myeloma Options

February 28th 2023

Amandeep Godara, MBBS, expands on the advantages and limitations of teclistamab monotherapy in patients with late-relapsed myeloma, discusses the best use of bispecific antibodies and CAR T-cell therapy in this population, and highlights ongoing efforts to mitigate the impact of treatment-related toxicities and improve accessibility across the paradigm.

New Approvals Continue to Shift Treatment Landscape in Hematologic Malignancies

February 27th 2023

Kathryn Maples, PharmD, BCOP, discusses recent approvals, updated labeling, and drug removals across leukemia, lymphoma, and multiple myeloma.

Progress in Disease Detection Sets the Stage for MRD’s Role in AML

February 27th 2023

For patients with acute myeloid leukemia, advances in targeting minimal residual disease represents the next wave of advances in the field and is necessary to cure this disease.

FDA Provides Guidance on Registrational Path for PDS0101 Triplet in HPV+, ICI-Refractory Head and Neck Cancer

February 27th 2023

The FDA has provided PDS Biotechnology Corporation with guidance on the required contents of a design for a potential registrational trial examining PDS0101 in combination with PDS0301 and an FDA-approved immune checkpoint inhibitor in patients with recurrent or metastatic human papillomavirus–positive, ICI-refractory head and neck cancer.

Frontline Ribociclib/Endocrine Therapy Generates Similar ORR to Combination Chemo in HR+/HER2– Advanced Breast Cancer

February 27th 2023

Yen-Shen Lu, MD, PhD, discusses the primary results of the RIGHT Choice trial and what they could mean for the use of ribociclib and endocrine therapy in this population.

Three Talented Researchers Recognized as Endowed Chairs

February 27th 2023

Huntsman Cancer Institute at the University of Utah congratulates three of their newest endowed chairs.

FDA Grants Priority Review to Nirogacestat for Desmoid Tumors

February 27th 2023

The FDA has granted a priority review to the new drug application for nirogacestat for the treatment of adult patients with desmoid tumors.

Triplet Regimen for Microsatellite Stable, BRAF V600E–Mutant mCRC Aims to Build Upon SOC

February 27th 2023

Because a positive correlation has been shown between expression of PD-L1 and BRAF V600E mutations in CRC, several combination therapies with checkpoint inhibitors and targeted agents are currently being explored.

Tislelizumab Plus Chemo Approved in China for PD-L1–High Advanced Gastric/GEJ Adenocarcinoma

February 27th 2023

The National Medical Products Administration of China has granted approval to tislelizumab in combination with fluoropyrimidine and platinum chemotherapy in the frontline treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with a high PD-L1 expression.

Lenvatinib Plus Pembrolizumab Generates Durable Responses in Advanced Endometrial Carcinoma

February 26th 2023

Lenvatinib in combination with pembrolizumab led to deep and durable tumor responses in patients with previously treated advanced endometrial carcinoma.

Davids Highlights Mounting Treatment Options in CLL

February 25th 2023

Patients with chronic lymphocytic leukemia, including those with difficult-to-treat disease classes such as double refractory, are quickly gaining more effective treatment options.

Liquid Biopsies and NGS Stand to Revolutionize Hematologic Malignancies

February 24th 2023

Andrew Ip, MD, delivers a keynote on the role for liquid biopsy and NGS in hematologic malignancies, including the barriers to implementing seamlessly into clinical practice.

Trastuzumab Deruxtecan Garners Approval in China for HER2+ Metastatic Breast Cancer

February 24th 2023

The National Medical Products Administration of China has approved the use of single-agent fam-trastuzumab deruxtecan-nxki in adult patients with unresectable or metastatic HER2-positive breast cancer who previously received 1 or more anti–HER2-based regimens.